Marta Caretto

Dr. Marta Caretto

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Maturitas
Verified
Journal Article
Closed access
MCMarta Caretto
Marta Caretto
Andrea GianniniAndrea Giannini
Andrea Giannini
EREleonora Russo
Eleonora Russo
TSTommaso Simoncini
Tommaso Simoncini

14 October 2021 in Endocrines
Verified
Journal Article
Open access
PDF file
Andrea GianniniAndrea Giannini
Andrea Giannini
MCMarta Caretto
Marta Caretto
AGAndrea Genazzani
Andrea Genazzani
TSTommaso Simoncini
Tommaso Simoncini
Menopause is the permanent cessation of menstrual cycles following the loss of ovarian follicular activity. Quality of life of postmenopausal woman is the result of a series of psychobiological transformations, that see in the reduction of sex hormones and steroids the etiopathogenetic determinant moment. Symptoms of menopause range from somatic side such as metabolic changes, increased cardiovascular disease, irregular vaginal bleeding, urogenital symptoms, vaginal dryness, osteoporosis and risk of bones fractures to changes of central nervous system as vasomotor symptoms, sleep disruption, mood changes, migraine, sexual dysfunctions. It is fundamental to know the mechanisms underlying changes in the central nervous system during menopause, related to hypoestrogenism, to be able to create appropriate target therapy for patients, improving their quality of life. In fact, the central nervous system is now one of the major targets of sex steroids that cannot be achieved disregard when dealing with the problem of choice of a particular type of MHT.

1 October 2019 in Maturitas
Verified
Journal Article
Closed access
MCMarta Caretto
Marta Caretto
AGAndrea Giannini
Andrea Giannini
TSTommaso Simoncini
Tommaso Simoncini

1 November 2019 in Maturitas
Verified
Journal Article
Closed access
RSR. Silvestri
R. Silvestri
IAI. Aricò
I. Aricò
EBE. Bonanni
E. Bonanni
MBM. Bonsignore
M. Bonsignore
MCMarta Caretto
Marta Caretto
TST. Simoncini
T. Simoncini

24 April 2015 in Molecular BioSystems
Verified
Journal Article
Closed access
PDF file
CMClaudia Martelli
Claudia Martelli
FIFederica Iavarone
Federica Iavarone
LDLuca D'ANgelo
Luca D'ANgelo
MAMorena Arba
Morena Arba
FVFederica Vincenzoni
Federica Vincenzoni
CDClaudia Desiderio
Claudia Desiderio
A top-down/bottom-up integrated proteomic approach based on LC-MS and 2-DE analysis was applied for comparative characterization of medulloblastoma and pilocytic astrocytoma posterior cranial fossa pediatric brain tumor tissues. Although rare, primary brain tumors are the most frequent solid tumors in the pediatric age. Among them the medulloblastoma is the prevalent malignant tumor in childhood while pilocytic astrocytoma is the most common, rarely showing a malignant progression. Due to the limited availability of this kind of sample, the study was applied to pooled tumor tissues for a preliminary investigation. The results showed different proteomic profiles of the two tumors and evidenced interesting differential expression of several proteins and peptides. Top-down proteomics of acid-soluble fractions of brain tumor homogenates ascribed a potential biomarker role of malignancy to β- and α-thymosins and their truncated proteoforms and to C-terminal truncated (des-GG) ubiquitin, resulting exclusively detected or over-expressed in the highly malignant medulloblastoma. The bottom-up proteomics of the acid-soluble fraction identified several proteins, some of them in common with 2-DE analysis of acid-insoluble pellets. Peroxiredoxin-1, peptidyl-prolyl cis–trans isomerase A, triosephosphate isomerase, pyruvate kinase PKM, tubulin beta and alpha chains, heat shock protein HSP-90-beta and different histones characterized the medulloblastoma while the Ig kappa chain C region, serotransferrin, tubulin beta 2A chain and vimentin the pilocytic astrocytoma. The two proteomic strategies, with their pros and cons, well complemented each other in characterizing the proteome of brain tumor tissues and in disclosing potential disease biomarkers to be validated in a future study on individual samples of both tumor histotypes.

1 January 2018
Verified
Book Chapter
Closed access
Paolo MannellaPaolo Mannella
Paolo Mannella
TSTommaso Simoncini
Tommaso Simoncini
MCMarta Caretto
Marta Caretto
AGAndrea Genazzani
Andrea Genazzani